...Thank you, Michelle, and those of you attending today's call. Dr. Shai Gozani, our President and CEO, is also participating in this Q2 review. NeuroMetrix is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. We design and deploy a recurring revenue business model in all of our products. These commercial products include the neurodiagnostic technologies of DPNCheck and ADVANCE, plus our chronic pain treatment technology, Quell. Our results for the second quarter of 2021 were just released. Overall, financial performance was in line with our expectations. We continue to make progress in positioning our commercial products for future growth, while supporting the ongoing research and development programs, which Shai will address shortly. Turning to the highlights of the Q2 earnings report. Q2 revenue was about $2.2 million, an improvement of 63% from $1.4 million in Q2 of last year. Last year results, however, were depressed...